Icon’s (ICLR) Sector Perform Rating Reiterated at Royal Bank Of Canada

Icon (NASDAQ:ICLR)‘s stock had its “sector perform” rating reissued by investment analysts at Royal Bank Of Canada in a research report issued on Monday,Benzinga reports. They currently have a $123.00 price target on the medical research company’s stock. Royal Bank Of Canada’s price objective suggests a potential upside of 3.17% from the stock’s current price.

A number of other research analysts have also weighed in on ICLR. Bank of America restated an “underperform” rating and set a $75.00 price objective on shares of Icon in a research report on Thursday, February 12th. TD Cowen raised shares of Icon from a “hold” rating to a “buy” rating and decreased their price objective for the stock from $183.00 to $120.00 in a research note on Wednesday, February 18th. Jefferies Financial Group set a $135.00 price target on shares of Icon and gave the stock a “buy” rating in a research note on Monday, February 23rd. Leerink Partners set a $125.00 price objective on shares of Icon in a research note on Monday, May 4th. Finally, Weiss Ratings cut shares of Icon from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 18th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $147.50.

Icon Stock Performance

NASDAQ ICLR opened at $119.22 on Monday. Icon has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a market cap of $9.63 billion, a price-to-earnings ratio of 16.13, a price-to-earnings-growth ratio of 3.04 and a beta of 1.23. The business has a 50-day moving average price of $109.72 and a 200-day moving average price of $144.56.

Hedge Funds Weigh In On Icon

Several large investors have recently made changes to their positions in the company. Sanctuary Advisors LLC boosted its holdings in Icon by 1.1% during the fourth quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after buying an additional 56 shares in the last quarter. Geneos Wealth Management Inc. boosted its stake in shares of Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares in the last quarter. New Wave Wealth Advisors LLC grew its position in shares of Icon by 5.1% during the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock valued at $270,000 after acquiring an additional 72 shares during the period. Signaturefd LLC grew its position in shares of Icon by 12.6% during the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock valued at $117,000 after acquiring an additional 72 shares during the period. Finally, Janney Montgomery Scott LLC increased its stake in shares of Icon by 0.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock valued at $4,363,000 after purchasing an additional 93 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.